Search

Your search keyword '"Ian M. Thompson"' showing total 1,051 results

Search Constraints

Start Over You searched for: Author "Ian M. Thompson" Remove constraint Author: "Ian M. Thompson"
1,051 results on '"Ian M. Thompson"'

Search Results

1. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment

2. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance

3. Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials

4. Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial

5. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

6. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

7. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer

8. Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities

9. Regulation of Cox-2 by Cyclic AMP Response Element Binding Protein in Prostate Cancer: Potential Role for Nexrutine

10. Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent

11. Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

12. The South Texas Health Status Review: A Health Disparities Roadmap.

13. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

14. Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial

15. Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer

16. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for 'large' cribriform prostatic adenocarcinoma

17. Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer

20. Perspective from Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

21. Data from Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression

22. Data from Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial

23. Supplementary Tables 1-3 from Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial

25. Data from Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

27. Data from Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach

28. Data from Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial

29. Finasteride and Prostate Cancer: New York Times Article from Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

31. Data Supplement from Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

35. Supplementary Tables 1-5 from Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial

37. Data from Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

39. Adjusted* General Linear Model to Compare The Impact of Metformin on PSA, BMI and LDL between Race/Ethnicity Groups from Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes

41. Supplementary Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

42. Supplemental Tables 1-4 from Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT

43. Supplemental Figure 1 from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

45. Data from Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent

46. Supplementary Materials from Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent

47. Supplementary Data - Table 1 from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

48. Supplementary Data - Table 2 from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

49. Data from Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer

50. Data from Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

Catalog

Books, media, physical & digital resources